Want to see TSE:LEXT full AI Analyst Report?
LEXT Stock Chart & Stats
C$0.08
>-C$0.01(-5.88%)
At close: 4:00 PM EDT
C$0.08
>-C$0.01(-5.88%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.34
Previous CloseN/A
Volume8.00K
Average Volume (3M)40.70K
Market Cap
C$2.13M
Enterprise ValueC$1.34
Total Cash (Recent Filing)C$278.52K
Total Debt (Recent Filing)C$8.00K
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt is a durable structural advantage: it reduces fixed financing obligations and bankruptcy risk, giving management financial flexibility to raise equity or deploy limited cash for operations or strategic options without servicing interest, important given ongoing losses.
Gold Industry ExposureOperating in the gold sector provides lasting structural demand as a store-of-value commodity and hedge asset. This industry positioning can support long-run asset value and potential investor flows into gold-linked businesses, offering optionality beyond short-term operational results.
Improved Capital Position (Equity Rebound)The TTM rebound in equity suggests recent recapitalization or financing that can extend runway. A stronger equity base gives the firm more durable capacity to fund exploration, maintain operations, or pursue strategic steps without immediate reliance on operating cash flow, supporting continuity.
Bears Say
Zero Recent RevenueSustained zero revenue undermines the firm's ability to develop a self-sustaining business model. Without recurring sales or commodity production, management must rely on external capital, limiting long-term profitability prospects and making the firm dependent on financing cycles rather than operational cash generation.
Persistent Cash BurnConsistent negative operating and free cash flow is a durable structural weakness: it erodes liquidity and increases financing risk. Repeated cash burn forces dilution or debt raises, constrains capital allocation for growth or exploration, and limits ability to respond to industry opportunities or shocks.
Negative Returns & Modest Asset BaseDeeply negative ROE and a small asset base indicate the company struggles to generate returns from capital. This persistent inability to compound shareholder value reduces long-term upside, limits capacity to scale operations, and heightens vulnerability to adverse market or funding conditions.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.04 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$2.13M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 52 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Based in Vancouver, Canada, Lexston Life Sciences Corp. operates as a biotechnology firm. The company offers comprehensive cannabis testing and research services across Canada, in addition to analytical evaluations for cannabis, pathogens, and toxins. A significant focus for Lexston involves the development and validation of standardized production methods for plant-derived psychedelics, with a view to supporting mental health and wellness initiatives.